Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALISADE Follow-on (ARC004)
NCT02993107Phase 3Completed
- Start
- Dec 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Allergy Immunotherapy
- Countries
- 9
01
Overview
Phase 3, open-label trial of peanut protein in peanut allergy (2 arms). Primary endpoint: Percentage of Subjects With Treatment-related Adverse Events up to 126 weeks. Started Dec 2016; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02993107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993107.